bioRxivNeurosciencePreprint
Assessing 42 inflammatory markers in 321 control subjects and 887 major depressive disorder cases: BMI and other confounders and overall predictive ability for current depression
Timothy R. PowelliD, Helena Gaspar, Raymond ChungiD, Aoife KeohaneiD, Cerisse GunasingheiD, Rudolf UheriD, Katherine Jean AitchisoniD, Daniel SoueryiD, Ole N MorsiD, Wolfgang Maier, Astrid W. Zobel, Marcella RietscheliD, Neven HenigsbergiD, Mojca Zvezdana DernovšekiD, Joanna HauseriD, Souci FrissaiD, Laura GoodwiniD, Matthew H. HotopfiD, Stephani L. HatchiD, David Andrew CollieriD, Hong WangiD
Abstract
Inflammatory markers such as cytokines represent potential biomarkers for major depressive disorder (MDD). Many, generally small studies have examined the role of single markers and found significant associations. We assessed 42 inflammatory markers, namely cytokines, in the blood of 321 control subjects and 887 MDD cases. We tested whether individual inflammatory marker levels were significantly affected by MDD case/control status, current episode, or current depression severity, co-varying for age, sex, body mass index (BMI), smoking, current antidepressant use, ethnicity, assay batch and study effects. We further used machine learning algorithms to investigate if we could use our data to blindly discriminate MDD patients, or those in a current episode. We found broad and powerful influences of confounding factors on log-protein levels. Notably, IL-6 levels were very strongly influenced by BMI (p = 1.37 x 10-43, variance explained = 18%), while Interleukin-16 was the most significant predictor of current depressive episode (p = 0.003, variance explained = 0.9%, q < 0.1). No single inflammatory marker predicted MDD case/control status when a subject was not in a depressed episode, nor did any predict depression severity. Machine learning results revealed that using inflammatory marker data with clinical confounder information significantly increased precision for differentiating MDD patients who were in an episode. To conclude, a wide panel of inflammatory markers alongside clinical information may aid in predicting the onset of symptoms, but no single inflammatory protein is likely to represent a clinically useful biomarker for MDD diagnosis or prognosis. We note that the potential influence of physical health related and population stratification related confounders on inflammatory biomarker studies in psychiatry is considerable.
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- approach: machine learning (classical)
- Citations
- 12
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Peripheral blood cell immunophenotyping reveals distinct subgroups of inflamed depression
M.-E. Lynall, L. Turner, … E. Bullmore·bioRxiv·Jul 18, 2019
- Disentangling causal relationships between inflammatory markers and depression: a bidirectional Mendelian randomization analysis
Christina Dardani, James Yarmolinsky, … Lindsey Isla Sinclair·bioRxiv·Nov 25, 2019
- Depression, GABA and age correlate with the plasma levels of inflammatory markers.
A. K. Bhandage, J. L. Cunningham, … B. Birnir·bioRxiv·Jul 2, 2019
- Brain Structural Correlates of an Impending Initial Major Depressive Episode
Anna Kraus, Katharina Dohm, … Udo Dannlowski·NeuropsychopharmacologyPeer-reviewed·Mar 12, 2025
- Treatment-resistant depression and peripheral C-reactive protein
Samuel Robin Chamberlain, Jonathan Cavanagh, … Edward Thomas Bullmore·The British Journal of PsychiatryPeer-reviewed·May 16, 2018
- Monocyte Dysregulation Defines an MDD-Specific Transcriptional Signature Closely Linked to Clinical MDD Traits
Laura Meier, Medhanie Assmelash Mulaw, … Karin M. Danzer·bioRxiv·Aug 12, 2025